The rate of late onset second malignancies was 31%, which was numerically higher than all CAD patients and those treated with rituximab/bendamustine combination (13% and 9%, respectively), although it did not reach statistical significance.
1
—
—
The rate of late onset second malignancies was 31%, which was numerically higher than all CAD patients and those treated with rituximab/bendamustine combination (13% and 9%, respectively), although it did not reach statistical significance.